Navigation Links
Study of successful drug targets could hasten development of new medications
Date:1/31/2008

Guidance from an innovative computational approach could speed up the process and cut down the cost of new drug development, researchers from the University of Chicago Medical Center and Columbia University suggest in a study to be published in the February 2008 issue of Genome Research, available early online.

The researchers analyzed specific properties of the human genes and proteins that serve as targets for nearly a thousand FDA-approved drugs. They identified a number of characteristics that were common among successful drug targetsand especially common among high-revenue drugs.

"To make a good drug, you need to find a good drug target," said Andrey Rzhetsky, PhD, professor of medicine at the University of Chicago and senior author of the study. "Here we provide guidelines for more efficient target screening. When a drug company must decide which target to pursue among pathologic pathways, this could provide useful estimates of each target's expected success rate."

Gleevec, Prozac, Viagra: these successful drugs all target specific proteins and provoke a desired response. They reward the people who need them, as well as to those who invent, manufacture and market them.

But he development of a new drug is complicated and expensive, "a fusion of art and science," the authors note. It involves finding an accessible drug target and a molecule that binds that target as selectively as possible. Then it must trigger a desirable physiological change.

But "every highly visible success," the authors note, "rests on an iceberg of invisible failures." Since the estimated cost of developing a new drug ranges from $800 million to $1.2 billion, "information that helps only a little bit," Rzhetsky said, "can still be quite valuable."

What characteristics, they asked, distinguished the targets that eventually became the focus of such successful drugs" How are these genes or proteins different from the tens of thousa
'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
772-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Conservation strategies must shift with global environmental change, says CU-Boulder study
2. Virginia Tech plant scientist leads study on genomics of parasitic plants
3. Smithsonian study: Sediment prediction tools off the mark
4. Prison study to investigate link between diet and behavior
5. Queens study connects obesity with nervous system
6. LSU, Yale team study agricultural impact on Mississippi River
7. Diet and lifestyle critical to recovery, says study
8. Scientists study the link between childrens nutrition and adult diseases
9. New Argonne study may shed light on protein-drug interactions
10. Sea otter study reveals striking variability in diets and feeding strategies
11. Study: weight-loss tips differ in African-American, mainstream magazines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. One major ... multimodal biometric systems. Multimodal biometric systems utilize more than ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center today ... School of Medicine. Funding for this $50 million capital project ... publicly launched next summer. The medical education ... Reynolds Tobacco Company complex, adjacent to 525@vine in Wake Forest ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... has been successful in gaining major European Union ... of biological samples, such as DNA, can be ... Europe. The Centre for Integrated Genomic Medical ... Medicine, is playing a key role in developing ...
... of researchers led by a first-year UC Davis faculty member ... should lead to far more accurate predictions of global climate ... online Wednesday (June 18) by the journal Nature . ... nitrogen cycle in temperate and tropical forests. Defying laws of ...
... a marine creature led by scientists at Scripps Institution of ... a key area of the tree of life. Linda ... from the United States, Europe and Asia, have deciphered and ... small, worm-like marine animal called amphioxus, also known as a ...
Cached Biology News:Manchester clears first hurdle in €170 million biobank building boom 2UC Davis researcher leads climate-change discovery 2Worm-like marine animal providing 2Worm-like marine animal providing 3
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... 4 , - Microplasmin Shows Clear Promise ... Achieving Macular Hole Closure and Traction Release,Without Need ... a biotechnology company,focused on vascular and eye diseases, ... IIT trial at the American Society of Retina ...
... Calif., Dec. 3 BioMarin,Pharmaceutical Inc. (Nasdaq and ... have initiated a program to develop an IgA ... shown to cleave IgA,complexes, the deposition of which ... treatment alternatives. BioMarin has executed a research,and option ...
... FRANCISCO, Dec. 3 /PRNewswire/ - Wall Street closed out ... week of November with gains, it,still posted a 4% ... its,biggest percentage gain in four and a half years ... prices and the,weakness in the economy," said G. Steven ...
Cached Biology Technology:ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 2ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 3ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 4BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 2BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 3BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 4Biotech Survives Market Turbulence in November 2Biotech Survives Market Turbulence in November 3Biotech Survives Market Turbulence in November 4Biotech Survives Market Turbulence in November 5
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
... / Mount is the standard water based ... especially for the permanent preservation of peroxidase ... is easy to use and exhibits excellent ... first aqueous mounting medium that permits the ...
... antibody development to targets including proteins and ... and cancer-specific surface antigens. A&Gs service ... completed in approximately 40 days (duration may ... antigens). Phase I: Immunization, test bleed ...
Biology Products: